Deutsche Bank AG Cuts Stock Holdings in Evolus, Inc. (NASDAQ:EOLS)

Deutsche Bank AG cut its stake in shares of Evolus, Inc. (NASDAQ:EOLS) by 43.6% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 307,769 shares of the company’s stock after selling 237,820 shares during the period. Deutsche Bank AG owned about 0.49% of Evolus worth $3,398,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of EOLS. JPMorgan Chase & Co. raised its holdings in Evolus by 63.5% during the third quarter. JPMorgan Chase & Co. now owns 169,926 shares of the company’s stock worth $2,753,000 after purchasing an additional 65,972 shares in the last quarter. KBC Group NV purchased a new position in Evolus in the 4th quarter valued at about $49,000. China Universal Asset Management Co. Ltd. lifted its holdings in Evolus by 10.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 13,426 shares of the company’s stock valued at $148,000 after purchasing an additional 1,291 shares in the last quarter. Rhumbline Advisers increased its stake in shares of Evolus by 2.2% during the 4th quarter. Rhumbline Advisers now owns 80,149 shares of the company’s stock valued at $885,000 after acquiring an additional 1,762 shares during the last quarter. Finally, Principal Financial Group Inc. increased its position in Evolus by 9.8% during the 4th quarter. Principal Financial Group Inc. now owns 33,370 shares of the company’s stock worth $368,000 after purchasing an additional 2,989 shares in the last quarter. Hedge funds and other institutional investors own 90.69% of the company’s stock.

Evolus Trading Up 0.6%

NASDAQ EOLS opened at $9.96 on Wednesday. The company has a market cap of $642.18 million, a price-to-earnings ratio of -10.94 and a beta of 1.11. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58. Evolus, Inc. has a twelve month low of $8.67 and a twelve month high of $17.82. The business’s fifty day moving average is $11.19 and its 200 day moving average is $12.24.

Insider Activity at Evolus

In other news, CFO Sandra Beaver sold 8,996 shares of Evolus stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total transaction of $119,286.96. Following the completion of the transaction, the chief financial officer now directly owns 173,583 shares in the company, valued at approximately $2,301,710.58. This trade represents a 4.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Karah Herdman Parschauer sold 12,888 shares of the business’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $12.99, for a total transaction of $167,415.12. Following the sale, the director now owns 32,183 shares of the company’s stock, valued at approximately $418,057.17. This represents a 28.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 86,241 shares of company stock valued at $1,048,666 in the last three months. Corporate insiders own 5.90% of the company’s stock.

Wall Street Analysts Forecast Growth

EOLS has been the topic of several research analyst reports. Needham & Company LLC restated a “buy” rating and set a $22.00 price objective on shares of Evolus in a research note on Thursday, May 8th. Barclays raised their price objective on Evolus from $22.00 to $25.00 and gave the company an “overweight” rating in a research note on Wednesday, March 5th. BTIG Research started coverage on Evolus in a research note on Thursday, April 17th. They issued a “buy” rating and a $21.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and set a $27.00 target price on shares of Evolus in a research report on Thursday, April 10th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $23.75.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.